Skip to main content
Fig. 7 | Arthritis Research & Therapy

Fig. 7

From: CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production

Fig. 7

CC-99677 administration resulted in sustained inhibition of ex vivo LPS-stimulated cytokine production in healthy volunteers. TNF levels (a) as percentage change from baseline measured in ex vivo LPS-stimulated whole blood from heathy volunteers until day 28 (lines show mean data for each group). TNF (b), MIP-1α (c), MIP-1β (d), and IL-6 (e) levels as percentage change from baseline measured in ex vivo LPS-stimulated whole blood from heathy volunteers dosed with 150 mg of CC-99677 (gray line represents the mean percent change in cytokine levels of 9 volunteers who received placebo; colored lines represent the percent change in cytokine level for individual CC-99677-dosed subjects; data shown until last day of dosing, day 14). Data calculated as the median percentage change from baseline. IL, interleukin; LPS, lipopolysaccharide; MIP, macrophage inflammatory protein; TNF, tumor necrosis factor

Back to article page